MacroGenics (MGNX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

MacroGenics

NasdaqGS•Healthcare•Biotechnology

$4.40+0.15(0.04%)Market closed

Market Cap

$262.65M

P/S

1.6x

P/B

6.1x

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

How this company scores

AverageMetricSide Score: 56/100

Strongest: Profitability (15/25); weakest: Cash & Earnings Quality (12/25).

Profitability15/25

Growth14/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality12/25

Strengths

Interest easily coveredCash-backed earningsProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 5.8x5y range 5.8x – 43.3x

P/S · 1.6x5y range 0.5x – 20.1x

Currently below its 20-quarter median.

P/B · 6.1x5y range 1.0x – 8.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $262.65M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $167.67M
Q. Revenue: $32.83M
TTM EBITDA: $-34.86M
TTM Op. Income: $-40.75M
Q. Op. Income: $-13.85M
TTM Net Income: $-14.59M
Q. Net Income: $19.52M
EPS: $0.31
Shares Out.: $63.59M

$167.67M in TTM revenue grew 1.3% YoY, reaching $32.83M last quarter. TTM EBITDA of $-34.86M and TTM operating income of $-40.75M show growth is flowing through to the bottom line. However, net income is negative at $14.59M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 3 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -40.0%
Op. Margin: -42.2%
Net Margin: 59.4%

Op. margin of -42.2% is up 123.1% YoY — cost efficiency is improving. Net margin at 59.4% Over the past year, operating margin is up 74% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.6x
P/B Ratio: 6.1x

P/S of 1.6x and P/B of 6.1x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $345.41M
Cash: $113.91M
Long-Term Debt: N/A
Book Value: $42.87M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-40.75M
TTM Free Cash Flow: $-65.54M
FCF Margin: -39.1%
FCF / Net Income: 4.5

TTM FCF of $-65.54M on $-40.75M in operating cash flow. The FCF / Net Income ratio of 4.5x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.